NO324207B1 - Farmasoytiske multiple enhetsformuleringer med tramadol, samt fremgangsmate til fremstilling derav. - Google Patents

Farmasoytiske multiple enhetsformuleringer med tramadol, samt fremgangsmate til fremstilling derav. Download PDF

Info

Publication number: NO324207B1
Authority: NO; Norway
Prior art keywords: formulations according; pharmaceutical formulations; release; pellets; active substance
Prior art date: 1996-07-25

Application number

NO19990261A

Other languages

English (en)

Norwegian (no)

Other versions

NO990261L (no

NO990261D0 (no

Inventor

Helmut Momberger

Marc Raber

Dieter Kuhn

Wolfgang Schmid

Original Assignee

Meda Pharma Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-25

Filing date

1999-01-21

Publication date

2007-09-10

1999-01-21 Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg

1999-01-21 Publication of NO990261L publication Critical patent/NO990261L/no

1999-01-21 Publication of NO990261D0 publication Critical patent/NO990261D0/no

2007-09-10 Publication of NO324207B1 publication Critical patent/NO324207B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 36
238000009472 formulation Methods 0.000 title claims abstract description 23
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 19
229960004380 tramadol Drugs 0.000 title claims abstract description 19
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims abstract description 19
238000000034 method Methods 0.000 title claims description 9
239000008188 pellet Substances 0.000 claims abstract description 51
239000007858 starting material Substances 0.000 claims abstract description 18
239000012528 membrane Substances 0.000 claims abstract description 17
239000000126 substance Substances 0.000 claims abstract description 16
239000002775 capsule Substances 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 6
239000013543 active substance Substances 0.000 claims description 53
230000000979 retarding effect Effects 0.000 claims description 19
239000011230 binding agent Substances 0.000 claims description 15
239000008194 pharmaceutical composition Substances 0.000 claims description 15
229920001249 ethyl cellulose Polymers 0.000 claims description 14
235000019325 ethyl cellulose Nutrition 0.000 claims description 14
229920001800 Shellac Polymers 0.000 claims description 12
235000013874 shellac Nutrition 0.000 claims description 12
230000003111 delayed effect Effects 0.000 claims description 11
239000001856 Ethyl cellulose Substances 0.000 claims description 10
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
239000004014 plasticizer Substances 0.000 claims description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
239000004208 shellac Substances 0.000 claims description 9
229940113147 shellac Drugs 0.000 claims description 9
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
230000006203 ethylation Effects 0.000 claims description 3
238000006200 ethylation reaction Methods 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
239000000454 talc Substances 0.000 claims description 3
229910052623 talc Inorganic materials 0.000 claims description 3
230000001476 alcoholic effect Effects 0.000 claims description 2
239000013078 crystal Substances 0.000 claims description 2
239000000314 lubricant Substances 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
239000000377 silicon dioxide Substances 0.000 claims description 2
235000012239 silicon dioxide Nutrition 0.000 claims description 2
230000007935 neutral effect Effects 0.000 claims 1
238000000338 in vitro Methods 0.000 description 13
239000000243 solution Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000012085 test solution Substances 0.000 description 7
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229960003107 tramadol hydrochloride Drugs 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
238000011835 investigation Methods 0.000 description 4
239000011159 matrix material Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000005095 gastrointestinal system Anatomy 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
101000607872 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 21 Proteins 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102100039918 Ubiquitin carboxyl-terminal hydrolase 21 Human genes 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
235000021438 curry Nutrition 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000004815 dispersion polymer Substances 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000021395 porridge Nutrition 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
238000001303 quality assessment method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000005507 spraying Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Glanulating (AREA)

NO19990261A 1996-07-25 1999-01-21 Farmasoytiske multiple enhetsformuleringer med tramadol, samt fremgangsmate til fremstilling derav. NO324207B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19630035A DE19630035A1 (de)	1996-07-25	1996-07-25	Tramadol Multiple Unit Formulierungen
PCT/EP1997/003934 WO1998004249A2 (de)	1996-07-25	1997-07-19	Tramadol multiple unit formulierungen

Publications (3)

Publication Number	Publication Date
NO990261L NO990261L (no)	1999-01-21
NO990261D0 NO990261D0 (no)	1999-01-21
NO324207B1 true NO324207B1 (no)	2007-09-10

Family

ID=7800815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990261A NO324207B1 (no)	1996-07-25	1999-01-21	Farmasoytiske multiple enhetsformuleringer med tramadol, samt fremgangsmate til fremstilling derav.

Country Status (28)

Country	Link
US (2)	US5955104A (cs)
EP (1)	EP0917463B1 (cs)
JP (1)	JP3631762B2 (cs)
KR (1)	KR100474793B1 (cs)
CN (1)	CN1111402C (cs)
AR (1)	AR008002A1 (cs)
AT (1)	ATE213408T1 (cs)
AU (1)	AU737121B2 (cs)
BG (1)	BG63708B1 (cs)
BR (1)	BR9710761A (cs)
CA (1)	CA2211284C (cs)
CZ (1)	CZ296964B6 (cs)
DE (2)	DE19630035A1 (cs)
DK (1)	DK0917463T3 (cs)
EE (1)	EE03742B1 (cs)
ES (1)	ES2171268T3 (cs)
HU (1)	HU227971B1 (cs)
IL (1)	IL127915A (cs)
NO (1)	NO324207B1 (cs)
NZ (1)	NZ333822A (cs)
PL (1)	PL188834B1 (cs)
PT (1)	PT917463E (cs)
RU (1)	RU2201223C2 (cs)
SK (1)	SK285300B6 (cs)
TW (1)	TW495363B (cs)
UA (1)	UA52679C2 (cs)
WO (1)	WO1998004249A2 (cs)
ZA (1)	ZA975408B (cs)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19630035A1 (de) *	1996-07-25	1998-01-29	Asta Medica Ag	Tramadol Multiple Unit Formulierungen
US6197347B1 (en) *	1998-06-29	2001-03-06	Andrx Pharmaceuticals, Inc.	Oral dosage for the controlled release of analgesic
US6312728B1 (en) *	1998-07-07	2001-11-06	Cascade Development, Inc.	Sustained release pharmaceutical preparation
DE19901686A1 (de)	1999-01-18	2000-07-20	Gruenenthal Gmbh	Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
DE19901687B4 (de) *	1999-01-18	2006-06-01	Grünenthal GmbH	Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
DE19940944B4 (de) *	1999-08-31	2006-10-12	Grünenthal GmbH	Retardierte, orale, pharmazeutische Darreichungsformen
CA2388560A1 (en)	1999-08-31	2001-03-08	Grunenthal Gmbh	Sustained-release form of administration containing tramadol saccharinate
EP2295043A1 (en)	1999-10-29	2011-03-16	Euro-Celtique S.A.	Controlled release hydrocodone formulations
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
AR030557A1 (es) *	2000-04-14	2003-08-27	Jagotec Ag	Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6620431B1 (en)	2000-04-17	2003-09-16	Charles Signorino	Shellac film coatings providing release at selected pH and method
JP5014554B2 (ja) *	2000-06-14	2012-08-29	ジェイカムアグリ株式会社	被覆生物活性粒状物の製造方法
EP1296666A2 (en) *	2000-07-06	2003-04-02	Delsys Pharmaceutical Corporation	Improved thyroid hormone formulations
AU2002227383B2 (en)	2000-10-30	2004-07-08	Euro-Celtique S.A.	Controlled release hydrocodone formulations
RU2174836C1 (ru) *	2000-12-15	2001-10-20	Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин"	Фармацевтическая композиция, обладающая анальгезирующим действием
DE10108122A1 (de)	2001-02-21	2002-10-02	Gruenenthal Gmbh	Arzneimittel auf Basis von Tramadol
US20030104976A1 (en) *	2001-07-23	2003-06-05	Gudarz Davar	Analgesic methods using endothelin receptor ligands
PE20030527A1 (es)	2001-10-24	2003-07-26	Gruenenthal Chemie	Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US8128957B1 (en)	2002-02-21	2012-03-06	Valeant International (Barbados) Srl	Modified release compositions of at least one form of tramadol
US20050182056A9 (en) *	2002-02-21	2005-08-18	Seth Pawan	Modified release formulations of at least one form of tramadol
AU2003211146B2 (en) *	2002-02-21	2007-07-19	Valeant International (Barbados) Srl	Controlled release dosage forms
CA2495564A1 (en) *	2002-08-15	2005-01-27	Euro-Celtique S.A.	Pharmaceutical compositions
ES2269591T3 (es) *	2002-11-27	2007-04-01	ORAMON-ARZNEIMITTEL GMBH & CO. KG	Procedimiento para la fabricacion de granulados que contienen un antidepresivo triciclico o tetraciclico, asi como preparaciones farmaceuticas que contienen estos granulados.
CN100500130C (zh) *	2003-01-23	2009-06-17	株式会社太平洋	缓释制剂及其制备方法
RU2223757C1 (ru) *	2003-03-04	2004-02-20	Закрытое акционерное общество "Брынцалов-А"	Препарат, обладающий анальгезирующим действием
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
DE10341414A1 (de) *	2003-09-05	2005-03-31	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
US20050053669A1 (en) *	2003-09-05	2005-03-10	Boehringer Ingelheim International Gmbh	Administration form for the oral application of poorly soluble acidic and amphorteric drugs
WO2005034859A2 (en) *	2003-10-03	2005-04-21	Elite Laboratories Inc.	Extended release formulations of opioids and method of use thereof
US8163114B2 (en) *	2004-04-07	2012-04-24	New Jersey Institute Of Technology	Netshape manufacturing processes and compositions
WO2006009403A1 (en) *	2004-07-22	2006-01-26	Amorepacific Corporation	Sustained-release preparations containing topiramate and the producing method thereof
JP4997109B2 (ja)	2004-09-01	2012-08-08	ユーロ−セルティークエス．エイ．	用量比例的な定常状態ｃａｖｅおよび定常状態ａｕｃ、ならびに、用量比例よりも小さい単回投与ｃｍａｘを有するオピオイド投薬形態物
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
CA2592605C (en)	2004-12-27	2010-12-07	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
US20060246003A1 (en) *	2004-12-27	2006-11-02	Eisai Co. Ltd.	Composition containing anti-dementia drug
US11311490B2 (en) *	2005-08-10	2022-04-26	Add Advanced Drug Delivery Technologies Ltd.	Oral preparation with controlled release
CA2628031C (en) *	2005-11-10	2013-03-05	Circ Pharma Research And Development Limited	Once-daily administration of central nervous system drugs
US20070185145A1 (en) *	2006-02-03	2007-08-09	Royds Robert B	Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20070190141A1 (en) *	2006-02-16	2007-08-16	Aaron Dely	Extended release opiate composition
US20070264346A1 (en) *	2006-02-16	2007-11-15	Flamel Technologies	Multimicroparticulate pharmaceutical forms for oral administration
US20070264335A1 (en) *	2006-05-09	2007-11-15	Sherman Bernard C	Modified release tablets comprising tramadol
WO2008094877A2 (en) *	2007-01-30	2008-08-07	Drugtech Corporation	Compositions for oral delivery of pharmaceuticals
CA2678367C (en) *	2007-03-02	2014-07-08	Farnam Companies, Inc.	Sustained release compositions using wax-like materials
CN105534936B (zh) *	2007-08-13	2020-07-31	Ohemo 生命科学股份有限公司	抗滥用药物、使用方法和制备方法
CN101095666B (zh) *	2007-08-14	2010-10-06	石药集团欧意药业有限公司	一种盐酸曲马多缓释片剂及其制备方法
CZ300468B6 (cs) *	2007-09-20	2009-05-27	Zentiva, A. S	Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
US20100285119A1 (en) *	2008-01-11	2010-11-11	Jubilant Organosys Ltd.	Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same
US20100003322A1 (en) *	2008-07-03	2010-01-07	Lai Felix S	Enteric coated hydrophobic matrix formulation
AU2009289464B2 (en) *	2008-09-04	2015-12-10	Farnam Companies, Inc.	Chewable sustained release formulations
FR2938431B1 (fr) *	2008-11-14	2013-12-20	Debregeas Et Associes Pharma	Nouvelle composition a base d'acide gamma-hydroxybutyrique
KR101689688B1 (ko)	2008-11-18	2016-12-26	유씨비 파마, 에스.에이.	２옥소１피롤리딘 유도체를 포함하는 지연 방출형 제형
US20100233259A1 (en) *	2008-12-12	2010-09-16	Pascal Grenier	Dosage form of ropinirole
FR2949061B1 (fr)	2009-08-12	2013-04-19	Debregeas Et Associes Pharma	Microgranules flottants
FR2949062B1 (fr)	2009-08-12	2011-09-02	Debregeas Et Associes Pharma	Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US20120009261A1 (en)	2010-07-06	2012-01-12	Grünenthal GmbH	Novel gastro-retentive dosage forms
US9730885B2 (en)	2012-07-12	2017-08-15	Mallinckrodt Llc	Extended release, abuse deterrent pharmaceutical compositions
US20140275038A1 (en)	2013-03-15	2014-09-18	Inspirion Delivery Technologies, Llc	Abuse deterrent compositions and methods of use
US10729685B2 (en)	2014-09-15	2020-08-04	Ohemo Life Sciences Inc.	Orally administrable compositions and methods of deterring abuse by intranasal administration
IT201800011125A1 (it) *	2018-12-14	2020-06-14	Dpl Pharma S P A	Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4415547A (en) *	1982-06-14	1983-11-15	Sterling Drug Inc.	Sustained-release pharmaceutical tablet and process for preparation thereof
JPS62103012A (ja) *	1985-10-23	1987-05-13	Eisai Co Ltd	多重顆粒
US5026560A (en) *	1987-01-29	1991-06-25	Takeda Chemical Industries, Ltd.	Spherical granules having core and their production
US5344657A (en) *	1988-04-27	1994-09-06	Elf Sanofi	Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them
US5260072A (en) *	1990-08-30	1993-11-09	Mcneil-Ppc, Inc.	Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
DE122004000032I2 (de) *	1991-09-06	2006-02-09	Mcneilab Inc	Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung
AU661723B2 (en) *	1991-10-30	1995-08-03	Mcneilab, Inc.	Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DE4329794C2 (de) *	1993-09-03	1997-09-18	Gruenenthal Gmbh	Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5395626A (en) *	1994-03-23	1995-03-07	Ortho Pharmaceutical Corporation	Multilayered controlled release pharmaceutical dosage form
US5411745A (en) *	1994-05-25	1995-05-02	Euro-Celtique, S.A.	Powder-layered morphine sulfate formulations
DE4428444A1 (de) *	1994-08-11	1996-02-15	Dresden Arzneimittel	Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen
US5567441A (en) *	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
DE19630035A1 (de) *	1996-07-25	1998-01-29	Asta Medica Ag	Tramadol Multiple Unit Formulierungen

1996
- 1996-07-25 DE DE19630035A patent/DE19630035A1/de not_active Withdrawn
1997
- 1997-06-19 ZA ZA9705408A patent/ZA975408B/xx unknown
- 1997-06-19 TW TW086108720A patent/TW495363B/zh not_active IP Right Cessation
- 1997-07-18 US US08/896,629 patent/US5955104A/en not_active Expired - Lifetime
- 1997-07-19 EP EP97935532A patent/EP0917463B1/de not_active Expired - Lifetime
- 1997-07-19 NZ NZ333822A patent/NZ333822A/xx not_active IP Right Cessation
- 1997-07-19 IL IL12791597A patent/IL127915A/en not_active IP Right Cessation
- 1997-07-19 RU RU99104404/14A patent/RU2201223C2/ru active
- 1997-07-19 PT PT97935532T patent/PT917463E/pt unknown
- 1997-07-19 DK DK97935532T patent/DK0917463T3/da active
- 1997-07-19 WO PCT/EP1997/003934 patent/WO1998004249A2/de not_active Ceased
- 1997-07-19 PL PL97331387A patent/PL188834B1/pl unknown
- 1997-07-19 EE EEP199900031A patent/EE03742B1/xx unknown
- 1997-07-19 ES ES97935532T patent/ES2171268T3/es not_active Expired - Lifetime
- 1997-07-19 KR KR10-1999-7000586A patent/KR100474793B1/ko not_active Expired - Lifetime
- 1997-07-19 AT AT97935532T patent/ATE213408T1/de active
- 1997-07-19 BR BR9710761A patent/BR9710761A/pt not_active Application Discontinuation
- 1997-07-19 CN CN97196651A patent/CN1111402C/zh not_active Expired - Lifetime
- 1997-07-19 SK SK98-99A patent/SK285300B6/sk not_active IP Right Cessation
- 1997-07-19 CZ CZ0018599A patent/CZ296964B6/cs not_active IP Right Cessation
- 1997-07-19 JP JP50846698A patent/JP3631762B2/ja not_active Expired - Lifetime
- 1997-07-19 DE DE59706441T patent/DE59706441D1/de not_active Expired - Lifetime
- 1997-07-19 UA UA99021086A patent/UA52679C2/uk unknown
- 1997-07-19 HU HU9903053A patent/HU227971B1/hu unknown
- 1997-07-19 AU AU38491/97A patent/AU737121B2/en not_active Expired
- 1997-07-24 CA CA002211284A patent/CA2211284C/en not_active Expired - Lifetime
- 1997-07-25 AR ARP970103383A patent/AR008002A1/es active IP Right Grant
1999
- 1999-01-21 NO NO19990261A patent/NO324207B1/no not_active IP Right Cessation
- 1999-02-09 BG BG103158A patent/BG63708B1/bg unknown
- 1999-07-08 US US09/349,564 patent/US6436438B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AR008002A1 (es)	1999-11-24
SK9899A3 (en)	1999-09-10
HK1020876A1 (en)	2000-05-26
HUP9903053A2 (hu)	2000-01-28
NO990261L (no)	1999-01-21
CZ18599A3 (cs)	1999-04-14
WO1998004249A2 (de)	1998-02-05
AU737121B2 (en)	2001-08-09
PL331387A1 (en)	1999-07-05
ATE213408T1 (de)	2002-03-15
JP3631762B2 (ja)	2005-03-23
NZ333822A (en)	1999-11-29
DE59706441D1 (de)	2002-03-28
RU2201223C2 (ru)	2003-03-27
AU3849197A (en)	1998-02-20
US6436438B1 (en)	2002-08-20
ES2171268T3 (es)	2002-09-01
EP0917463B1 (de)	2002-02-20
JP2000515871A (ja)	2000-11-28
EE9900031A (et)	1999-08-16
HU227971B1 (en)	2012-07-30
EP0917463A2 (de)	1999-05-26
CN1226824A (zh)	1999-08-25
EE03742B1 (et)	2002-06-17
DE19630035A1 (de)	1998-01-29
BG103158A (en)	1999-08-31
TW495363B (en)	2002-07-21
CA2211284C (en)	2001-10-23
BG63708B1 (bg)	2002-10-31
UA52679C2 (uk)	2003-01-15
US5955104A (en)	1999-09-21
ZA975408B (en)	1998-01-05
CN1111402C (zh)	2003-06-18
KR100474793B1 (ko)	2005-03-08
NO990261D0 (no)	1999-01-21
WO1998004249A3 (de)	1998-04-30
PT917463E (pt)	2002-07-31
KR20000029530A (ko)	2000-05-25
PL188834B1 (pl)	2005-04-29
SK285300B6 (sk)	2006-10-05
IL127915A (en)	2001-08-08
CZ296964B6 (cs)	2006-08-16
IL127915A0 (en)	1999-11-30
DK0917463T3 (da)	2002-06-10
HUP9903053A3 (en)	2000-02-28
BR9710761A (pt)	1999-08-17
CA2211284A1 (en)	1998-01-25

Legal Events

Date	Code	Title	Description
2017-07-31	MK1K	Patent expired

Publication	Publication Date	Title
AU737121B2 (en)	2001-08-09	Tramadol multiple unit formulations
FI78835B (fi)	1989-06-30	Foerfarande foer framstaellning av en ny dipyridamol-retardform.
CA2377167C (en)	2009-06-09	Multilayered tablet for administration of a fixed combination of tramadol and diclofenac
AU623225B2 (en)	1992-05-07	Pharmaceutical composition providing the sustained release of valproic acid
KR101834033B1 (ko)	2018-04-13	주의력 결핍 장애 치료용 고체 경구 제약 조성물
US5122384A (en)	1992-06-16	Oral once-per-day organic nitrate formulation which does not induce tolerance
RU2325163C2 (ru)	2008-05-27	Композиции с пролонгированным высвобождением, включающие ламотригин
NO300758B1 (no)	1997-07-21	Fremgangsmåte for fremstilling av en smaksmaskert tablett som kan tygges og som har egenskaper med regulert frigjörelse
EP1185253B1 (de)	2004-03-03	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
EP3154523A1 (en)	2017-04-19	Formulation for oral administration containing mesalazine
KR20090029830A (ko)	2009-03-23	소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
BRPI0621633A2 (pt)	2011-12-13	composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada
WO2009069089A9 (en)	2009-12-10	Levetiracetam controlled release composition
BRPI0611272A2 (pt)	2011-11-16	formulações de quinina
TWI679012B (zh)	2019-12-11	含有達方吡啶的緩釋口服滲透錠劑及其用途
JPH02164821A (ja)	1990-06-25	新規な投与形態
JP2005526739A (ja)	2005-09-08	コレステロール濃度を低下させる活性成分を含み、活性成分が遅延放出される薬剤
CN101756981B (zh)	2013-04-10	一种布洛氯雷伪麻缓释制剂及其制备方法
CN101002755A (zh)	2007-07-25	一种组合脉冲释放制剂及其制备方法
US8173164B2 (en)	2012-05-08	Oral administration forms for administering a fixed tramadol and diclofenac combination
RU2292877C2 (ru)	2007-02-10	Лекарственная ретард-форма, содержащая сахаринат трамадола
MXPA99000903A (en)	1999-06-01	Tramadol multiple unit formulations
NO175514B (no)	1994-07-18	Fremgangsmåte for fremstilling av kuler for fremstilling av produkter med kontrollert frigivelse
KR20010069756A (ko)	2001-07-25	소염진통제인 아세메타신을 함유하며 장관내 특히대장에서의 약물 방출 속도가 조절되는 약물 전달 체계에대한 약제학적 경구용 조성물 및 그에 대한 제조방법